FHLC Fact Sheet: Fidelity MSCI Health Care Index ETF
Share
$86.45
close, Nov 18, 2026
Over the year to Nov 18, 2026, FHLC returned +19.8% in total and charged 0.08% a year.
- 1-year total return
- +19.8%
- VHT +19.7% to Nov 18, 2026
- Expense ratio
- 0.08%
- a year
- Net assets
- $4.0bn
- on Oct 31, 2026
- Net flow, 12 months to Jul 31, 2026
- +$288m
- monthly N-PORT basis to Jul 31, 2026
Growth of $10,000, 1 year
FHLC $11,981 +19.8% · VHT $11,967 +19.7% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.
Returns
WindowTotal return
1 month+2.6%
3 months+1.8%
Year to date+17.6%
1 year+19.8%
3 years+50.1%
5 years+40.7%
Total return, distributions reinvested, each window to Nov 18, 2026.
Ten largest positions
HoldingWeight
Eli Lilly & Co13.35%
Johnson & Johnson8.93%
AbbVie Inc6.42%
UnitedHealth Group Inc5.44%
Merck & Co Inc4.66%
Thermo Fisher Scientific Inc3.09%
Amgen Inc3.00%
Abbott Laboratories2.66%
Gilead Sciences Inc2.34%
Pfizer Inc2.06%
FHLC top ten by weight, 51.9% of the fund, of its 334 equity positions, from the holdings filed for Jul 31, 2026.
Facts
Equity fund · Tracks the MSCI USA IMI Health Care 25/50 Index · First traded Oct 24, 2013 · Benchmark MSCI USA IMI Health Care 25/50 Index, measured by VHT, which tracks the same index